Evidence map›Paper›PMID 39319169›Full record

ArticleHeliyon2024

Efficacy of surufatinib in the treatment of advanced parathyroid carcinoma: A case report.

Zhiyong Yu, Jie Zhou, Fuqiang Li, Xiaojun Xie, Liang Hu, Linghui Chen, Xuan Li, Qijun Zhang, Junli Wang, Yijun Wu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhiyong YuDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Jie ZhouDepartment of Pathology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Fuqiang LiDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Xiaojun XieDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Liang HuDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Linghui ChenDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Xuan LiDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Qijun ZhangDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Junli WangDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.
Yijun WuDepartment of Thyroid Surgery, First Affil1ated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parathyroid cancer is an extremely rare form of neuroendocrine malignancy. Apart from surgery, the effectiveness of chemotherapy and radiotherapy is limited, and the efficacy of targeted drugs remains unclear. In this study, we demonstrate the therapeutic effectiveness and adverse reaction of the targeted drug surufatinib in treating a case of parathyroid cancer, and concurrently review the recent advancements in the treatment of parathyroid cancer. The patient, a 55-year-old male, underwent his first surgery for a "right cervical mass" in May 2011. Postoperative pathology indicated an atypical adenoma of the parathyroid gland. In August 2016, the patient underwent a second surgery for recurrence of the right cervical tumor, with a pathological diagnosis of parathyroid cancer based on clinical history. In November 2017, the patient underwent a third surgery for recurrence of the right cervical tumor. In December 2017, the patient underwent adjuvant external radiation therapy. In August 2022, the patient developed spinal and lung metastases and underwent spinal surgery. Subsequently, the patient received three rounds of chemotherapy on October 5, 2022, October 28, 2022, and November 18, 2022, but the tumor showed slight enlargement. In January 2023, the patient began treatment with surufatinib. After two cycles of treatment, the tumor showed regression. Given the scarcity of systemic treatment options for parathyroid cancer, the targeted drug surufatinib may offer a promising potential treatment option.

Indexed as

Neuroendocrine tumorParathyroid carcinomaRare tumorTargeting drugTreatment

Identifiers

PMID39319169
PMCPMC11419863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.